Newbridge Acquisition

For investors tracking redemption mechanics, extension votes, or sponsor behavior, this filing provides no operational lever or timeline shift. Its sole substantive contribution is the contractual recognition of a reporting group comprising Wealth Path Holdings Limited, Yongsheng Liu (Director), and Jining Li, which indicates consolidated beneficial ownership reporting rather than strategic or financial developments. Because the agreement contains no claims regarding customers, revenue streams, addressable markets, technology roadmaps, partnership structures, litigation posture, or executive appointments, it does not inform target evaluation or deal progression. Investors requiring details on aggregate position size, voting alignment, or potential combination implications must consult the primary Schedule 13G statement referenced in the SEC index [0001213900-26-015623], as this exhibit carries no commercial or structural disclosures beyond its procedural scope.

Shareholders can now map their redemption window against the firm 15-to-21-month deadline originating from the February 2, 2026 closing date, with extension triggers and costs explicitly defined. The trust balance mechanics establish the baseline for liquidation or redemption distributions, subject to the stated requirement that targets hold at least 80% of the trust account value at signing. Management’s presentation of a $1,769,619 working capital deficit and $620,122 accumulated deficit, flagged by Enrome LLP as raising substantial doubt about going concern status, indicates that operating runway relies heavily on the unsecured sponsor loans or released trust interest. The explicit waiver of sponsor redemption rights on founder shares and the 1/8-rights conversion formula dictate the post-combination equity calculus for public holders evaluating whether to seek approval, tender shares, or wait out the rights expiration.

For investors monitoring sponsor conduct and deal progress ahead of the 2027-05-02 deadline, Liu Yongsheng’s open-market acquisition signals direct capital deployment into NBRG independent of the trust account. The filing contains no substantive claims regarding customers, revenue, market size, strategy, technology, partnerships, or litigation. Any inference about management confidence derives solely from the insider’s self-reported trading activity documented in this Form 4.

Per the form’s disclosures, Li Jining voluntarily acquired 186,250 shares on the open market on 2026-02-02, establishing a confirmed equity position of 186,250 shares. This provides tracked evidence of internal capital deployment independent of sponsor or anchor allocations, which investors monitor when assessing managerial alignment and pre-merger confidence. The filing introduces no claims regarding customer bases, revenue streams, market size, strategic pivots, technological capabilities, partnership structures, or ongoing litigation, and therefore does not alter the mechanical timeline or valuation framework beyond documenting this specific insider transaction.

Establishes the SPAC's initial trust value of $10.00 per public share, confirms the 15-21 month deadline for a business combination, details the lock-up and redemption provisions, and sets the contractual framework for future transactions. The filing also reveals the sponsor's private placement, insider letter agreements, and registration rights, all of which are standard but essential for tracking sponsor conduct and potential redemptions.

For investors tracking redemption timelines and sponsor alignment, the filing confirms that extension periods bypass shareholder votes and redemption opportunities, effectively transferring timeline control entirely to Wealth Path Holdings Limited. The documented anti-dilution mechanism ensures that any equity or equity-linked securities deployed to close a merger will disproportionately dilute public shareholders unless explicitly waived. Attributed to management disclosures, prior leadership experience spans past SPAC transactions with Scienjoy Inc.

Resetting the pricing period advances the anticipated IPO closing date, which immediately triggers the start of the company’s 15-month business combination window (extendable up to two additional three-month periods, totaling 21 months). According to the prospectus, extending requires the sponsor to deposit $500,000 ($0.10 per share) or up to $575,000 ($0.10 per share with full over-allotment) for each three-month extension, and public shareholders are explicitly barred from voting on or redeeming shares in connection with any such extension.

The SPAC has yet to consummate its public offering and has a substantial going concern risk (negative working capital deficit of $742,635, accumulated deficit of $551,586, and total shareholders' deficit of $526,586). The sponsor has provided $799,843 in loans, signaling liquidity support, but the Company's ability to survive until a business combination is highly uncertain. With the S-1 effective but no IPO closed, there is no trust account and no redemption calendar to track. The forfeiture of 1.44 million sponsor shares reduces potential dilution for future public investors.

This filing moves the SPAC closer to completing its initial public offering by providing updated financial and offering information to the SEC. For investors, it confirms the SPAC's structure, trust size, timeline, and sponsor terms. The updated financials show the company has a working capital deficit and going concern uncertainty, which is typical for a pre-IPO SPAC. The extension provisions allow for up to 21 months to complete a business combination. The document also details the founder share forfeiture, reducing insider ownership concentration.

This filing establishes the terms of the SPAC's IPO, including the trust amount ($50 million), redemption rights, extension mechanics, and sponsor compensation. It confirms the deadline for a business combination is 15 months from the closing of the offering (or up to 21 months with sponsor deposits). The trust per-share value is $10.00 at IPO, but the current trust/share of $9.29 (as noted in the user's context) suggests subsequent changes. The document also provides details on the sponsor's investment, potential conflicts of interest, and the risk that the SPAC may not successfully complete a merger.

Regulatory commentary of this nature precedes registration effectiveness and does not recalibrate investor liquidity parameters, cash preservation targets, or corporate governance obligations tied to the SPAC lifecycle. Compliance requires precise statutory drafting around capital account limitations and creditor priority structures. Delays in amending the S-1 may postpone acceleration approvals without impacting the fundamental economic architecture of the public offering or the sponsor’s fiduciary posture.

This filing is the foundational IPO registration for NBRG. The structure and timeline described — 15-month deadline, unilateral extension ability, 20% redemption cap, and sponsor economics — will govern all future redemption decisions, trust value computations, and deal negotiations. The absence of any target identification confirms the blank-check status. The sponsor's nominal cost for founder shares ($0.017 vs. $10.00 public offering price) represents a significant misalignment of incentives with public shareholders.

The recalibrated redemption math and precise trust dollar amounts directly define the liquidity threshold and public share count subject to cash-out rights ahead of any merger vote, allowing investors to price redemption economics against prevailing trust conditions. The added additional financing disclosure signals potential structural capital gaps that could trigger sponsor or PIPE commitments, shifting deal execution risk. The tax terminology adjustment is a routine compliance clean-up that does not alter substantive economic terms or timeline.

The sponsor-funded extension structure allows insiders to delay dissolution and preserve trust liquidity without public voting costs, aligning sponsor economic timelines with extended deal-hunting periods despite the documented history of high-redemption predecessors (up to 98% of public shares redeemed in prior vehicles managed by the same team). The 20% redemption cap for affiliated parties materially reduces potential liquidity drains from concentrated holders during a business combination vote, altering traditional shareholder leverage dynamics.

Because the SEC explicitly ties the additional financing inquiry to investor protection under Item 1602(b)(5) of Regulation S-K, any gap between the trust balance and the target acquisition valuation will likely force Newbridge Acquisition to raise outside capital, which the staff warns will materially alter the position of unaffiliated shareholders.

Establishes the definitive terms for public capital and redemption rights while highlighting severe structural and geopolitical headwinds. The prospectus documents immediate dilution of $2.36 to $2.40 per share against the $10.00 offering price, driven by the sponsor’s nominal $25,000 purchase of 1,437,500 Class B ordinary shares and concurrent sale of 175,000 private units at $10.00. Internal incentives favor rapid deal completion regardless of valuation quality, as founder shares and private units become worthless upon failure to combine.

This submission advances the S-1 registration timeline toward effectiveness, which establishes the regulatory framework for any future definitive merger vote, corresponding redemption window, and potential deadline extensions. The codified $5,000,001 net tangible asset floor structurally limits maximum shareholder redemptions to prevent exchange delisting triggers, while the explicit acknowledgment that offering proceeds fall short of the disclosed $650 million to $2 billion target range signals anticipated PIPE or debt financings that may introduce leverage or equity dilution ahead of a deal close. Enhanced sponsor disclosures regarding Wealth Path Holdings Limited, compensation flow paths, and director/officer exposure to Chinese regulatory oversight improve visibility into promoter alignment and geopolitical risk concentration. All operational claims, valuation ranges, and accounting references originate from the Company’s management and outside counsel responding to SEC feedback, as documented in the accompanying Amended Draft Registration Statement.

Per the SEC staff’s review, resolving these comments is prerequisite to finalizing the offering and advancing toward the 2027-05-02 deadline without triggering redemption traps or dilution disputes. On substantive grounds, staff highlight that the SPAC targets companies with significant revenue growth potential valued between $650 million and $2 billion, and challenge the assumption that no ordinary shares, convertible equity, or debt securities will be issued to bridge the gap between initial offering proceeds and target valuations.

The filing locks in the initial redemption floor and trust mechanics, which Newbridge states will hold $10.00 per public share upon closing. Investors can now model extension costs against potential dilution, noting that founder shares were acquired for $25,000 (approximately $0.017 per share) and will convert on a one-for-one basis, subject to anti-dilution adjustments. Up to $1,500,000 in sponsor working capital loans may convert into private units at $10.00 per unit.

What changed: Form 8-K filed as a Rule 425 written communication announcing the execution of a definitive Business Combination Agreement between SPAC Newbridge Acquisition Limited and Startech Group Inc. Newbridge Acquisition (NBRG) entered into a Business Combination Agreement to acquire Startech Group Inc., a U.S.-based AI technology company with fintech-enablement capabilities, operating through two segments: aquaporin functional water (AQP Water) and the StarOS AI agent operating system platform. The SPAC will re-domicile from the British Virgin Islands to Delaware, then merge with Startech. Startech equityholders will receive 100 million shares of the combined company at an implied $10.00 per share ($1 billion aggregate consideration). The sponsor, Wealth Path Holdings, has committed via a Support Agreement to vote in favor and not redeem its shares. The closing is subject to shareholder approvals, SEC effectiveness of an S-4, Nasdaq listing, and other customary conditions, with an outside date of November 2, 2027. The trust per share is $9.29 as of the filing, and the SPAC has a deadline of May 2, 2027. Why it matters: This filing establishes the definitive terms for the SPAC merger, triggering redemption mechanics and setting the timeline for shareholder vote. The target combines a bottled water business with an AI platform, which may raise questions about revenue generation and valuation. The $1 billion enterprise value relative to trust value implies potential upside but also risk of high redemptions given the trust value near $9.29. The outside date of November 2027 provides buffer, but the SPAC's May 2027 deadline may require an extension if the deal slips. Sponsor lock-in supports vote passage.

What changed: A Schedule 13G beneficial ownership compliance exhibit filed under Securities Exchange Act rules, specifically reported by Highbridge Capital Management, LLC regarding Newbridge Acquisition (NBRG). This routine regulatory filing confirms that Highbridge Capital Management, LLC holds securities in NBRG. The submitted excerpt does not disclose the percentage of beneficial ownership, acquisition dates, cost basis, or transaction history. As reported by Highbridge Capital Management, LLC, there is no indication that the holder’s position alters the redemption deadline of 2027-05-02, the trust value per share of $9.29, any proposed extension, the status of a business combination, or sponsor conduct. Furthermore, according to the filing, the document contains no claims, metrics, or updates regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. Why it matters: For investors monitoring SPAC capital structures and shareholder alignment, institutional ownership disclosures help gauge potential voting influence and redemption pressure. Because this Schedule 13G excerpt lacks ownership thresholds, amendment flags, or trading narratives, it does not currently signal active participation in deal negotiation or redemption strategy. Tracking whether Highbridge Capital Management, LLC files subsequent Schedule 13D amendments, proxy statements, or redemption notices before the 2027-05-02 deadline will determine if this position materially affects capital deployment, extension voting, or post-merger liquidity.

What changed: This document is a Schedule 13G beneficial ownership report that includes two identical Power of Attorney exhibits executed by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC, appointing eighteen named individuals as attorneys-in-fact to submit Securities Exchange Act filings on behalf of the firm. Regarding redemption deadlines, trust value, extensions, deal progress, and sponsor conduct, this filing introduces no alterations. Newbridge Acquisition’s trust per share remains fixed at $9.29, the business combination deadline stays set for 2027-05-02, the currently announced deal status is unchanged, and sponsor conduct is unaffected. The sole mechanical update is Goldman Sachs refreshing its internal roster of authorized signatories for future regulatory submissions, explicitly superseding prior powers of attorney dated July 29, 2024 and October 1, 2024. Why it matters: This purely administrative authorization carries zero impact on public shareholder voting, redemption pricing, or merger execution timelines. It contains no forward-looking statements, operational metrics, or strategic claims about customers, revenue, market size, technology, partnerships, litigation, or personnel beyond listing the eighteen appointed employees and confirming that Carey Ziegler, Managing Director, countersigned both grants on July 16, 2025. The instruments remain valid until July 16, 2026 or upon an employee’s separation, and they are governed by New York law. The filing simply confirms continued institutional position reporting without adjusting any economic or structural parameters of the SPAC vehicle.

What changed: Schedule 13G beneficial ownership report. Aristeia Capital, L.L.C. filed this Schedule 13G to disclose beneficial ownership. Bearing on the SPAC mechanics: the excerpt contains no reports altering the redemption deadline, no adjustments to the trust account, no indications of an extension vote, no updates on deal progress, and no signals regarding sponsor conduct. Regarding other substance: the document contains no claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. All disclosed positioning derives from Aristeia Capital, L.L.C. Why it matters: This functions as a routine compliance exhibit tracking institutional stake registration. It introduces no mechanical triggers that would compress redemption windows, mandate extension funding, advance merger execution, or reflect sponsor conduct changes. Investors monitoring NBRG should treat it as standard regulatory housekeeping absent of material operational or financial disclosures.

What changed: Quarterly report on Form 10-Q for the period ended March 31, 2026, the first such report after the SPAC's IPO on February 2, 2026. Newbridge Acquisition completed its IPO of 5,750,000 units (including over-allotment) at $10.00 per unit, generating $57.5 million in gross proceeds. Simultaneously, the sponsor purchased 186,250 private units for $1.8625 million. The trust account holds $57,806,561 as of March 31, 2026. Net income was $95,982 for the quarter, compared to a net loss of $51,857 in the prior-year period. The company has a working capital deficit of $501,095 and an accumulated deficit of $524,140. Management discloses substantial doubt about going concern due to the mandatory liquidation requirement if no business combination is completed within the 15-month combination period (extendable to 21 months). Total liabilities are $2.347 million, consisting of a promissory note to the sponsor. No business combination target has been selected nor have substantive discussions been initiated. The company also provides details on extension note provisions allowing the sponsor to deposit $500,000–$575,000 per three-month extension. Why it matters: This filing establishes the post-IPO financial baseline, including trust value per share ($9.07 redemption value), cash burn, and sponsor loan amounts. It confirms the SPAC is in the early search phase with a May 2, 2027 ultimate deadline (assuming no extensions). The going concern qualification and working capital deficit signal potential liquidity risk if a deal is not consummated promptly. The extension mechanism and sponsor's loan commitments are key for evaluating sponsor alignment. Trust accretion and redemption mechanics are detailed, aiding redemption deadline tracking.

What changed: Schedule 13G beneficial ownership report. The filing text identifies four reporting persons—Wolverine Asset Management, LLC, Wolverine Holdings, LLC, Christopher L. Gust, and Robert R. Bellick—but discloses no percentage of shares beneficially owned, no transaction dates, no aggregate share counts, and no purchase prices. Because the text omits all quantitative holdings data, it provides zero information regarding redemption mechanics, the $9.29 trust/share, the 2027-05-02 deadline, extension voting procedures, target company progress, or sponsor conduct. The document also contains no attributable claims or factual assertions regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. Why it matters: For investors monitoring deadline exposure, trust sufficiency, or merger sequencing, this submission is procedurally routine and substantively opaque. Without disclosed ownership percentages or volume, it is impossible to determine whether these Wolverine-affiliated parties have crossed disclosure thresholds that would grant them meaningful voting leverage over an extension amendment, a business combination vote, or tender behavior ahead of the May 2027 window. The filing confirms regulatory awareness by these entities but offers no verifiable signal of capital commitment, governance stance, or alignment with sponsor timelines until a subsequent amendment supplies the missing numeric data.

What changed: 10-K annual report for fiscal year ended December 31, 2025, pre-IPO status with subsequent IPO in February 2026. Filing shows first full-year financials after formation; IPO closed after year-end; trust account of $57.5M established; sponsor loans of $5.4M; working capital deficit of $3.6M; going concern doubts raised. Why it matters: Confirms redemption deadline of 15 months from IPO (May 2027) with possible extensions; trust per share $10.00; discloses sponsor debt and liquidity risks; no business combination announced yet.

What changed: Form 8-K current report and accompanying press release filed by Newbridge Acquisition Limited announcing the separation and separate trading of the Class A ordinary shares and Rights underlying its listed Units. Per the press release issued by the Company and attributed to Chief Executive Officer Yongsheng Liu, commencing March 23, 2026, unit holders may elect to separate their Units. The filing details that each Unit comprises one Class A ordinary share and one Right entitling the holder to receive one-eighth of one Class A ordinary share upon consummation of an initial business combination. Separated securities will trade on Nasdaq under the symbols NBRG and NBRGR, while unseparated Units continue as NBRGU. The Company instructs holders to direct their brokers to contact transfer agent VStock Transfer LLC to process the separation. Why it matters: This announcement operationalizes the registration statement (File No. 333-289966), which the Company states became effective on September 30, 2025, with a post-effective amendment declared effective on December 18, 2025. It provides the mechanical pathway for trading pre-combination components ahead of the fixed May 2, 2027 deadline, while leaving the documented trust value of $9.29 per share unchanged. The filing contains no new claims regarding target identification, projected revenue, market size, technology, partnerships, or litigation, nor does it indicate alterations to sponsor conduct. It solely updates security structure logistics and compliance status relative to the pending business combination.

What changed: Routine compliance exhibit: A Form 8-K current report (Item 8.01 Other Events) disclosing a non-binding memorandum of understanding to explore a de-SPAC transaction. First, the Registrant states that on February 27, 2026, Newbridge Acquisition Limited and Starcoin Group Limited entered into an MOU to explore a potential business combination. Second, the filing confirms there have been no changes to the $9.29 trust/share balance, the May 2, 2027 liquidation deadline, or any sponsor conduct or leadership changes. Third, it specifies that the MOU is not legally binding, requires reasonable endeavours for due diligence, and will terminate 180 days after its date or upon signing a definitive agreement. Additionally, the filing identifies Starcoin Group Limited as formerly known as Innovative Pharmaceutical Biotech Limited, a Cayman Islands entity continued in Bermuda, trading on The Stock Exchange of Hong Kong Limited under stock code 399. Why it matters: For investors tracking redemption mechanics, this filing opens a new deal pipeline but does not immediately alter trust distribution schedules, proxy voting requirements, or extension triggers. Because the MOU lacks binding terms and financial specifics, cash outflows and shareholder liquidity options remain suspended. The 180-day exploration window establishes the next material checkpoint: if definitive agreements are not executed, management will likely need to secure a trust extension or initiate a fresh target search, which would directly reset future redemption windows and capital deployment timelines.

What changed: A Schedule 13G, which is a routine regulatory compliance exhibit and beneficial ownership report. According to the filing text, Space Summit Capital LLC is named as the reporting holder; the excerpt discloses no share counts, percentages, or transaction dates to indicate a change in beneficial ownership that would impact redemption mechanics, trust value preservation, or sponsor conduct. Why it matters: Investors tracking the stated deadline and trust amount cannot determine from this excerpt whether Space Summit Capital LLC intends to redeem shares, vote for an extension, or enter into side letter agreements limiting redemptions. The document contains no claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. Future amendments must be monitored for explicit disclosures on deal progress, voting power, or alignment with the sponsor.